AstraZeneca Plc’s

(NYSE:

AZN

) coronavirus vaccine development program could hit by further delays,hometown heroes banners as the Food and Drug Administration has widened the scope of its probe into the halted trial, Reuters

reported

Wednesday.

What Happened:

The federal agency is inquiring whether side effects similar to the one seen in the COVID-19 vaccine trial — transverse myelitis — also emerged in trials of other vaccines designed by Oxford University, AstraZeneca's partner, Reuters said, citing people familiar with the matter.

The vaccines reportedly under review use a modified adenovirus as a vector and target illnesses such as the Middle East Respiratory Syndrome and the flu.

Oxford’s vaccines use a chimpanzee adenovirus, ChAdOx1, unlike other vaccine developers that use a human variant.

A review of research papers by Reuters found that in one trial, a serious side effect event cited by researchers was classified as unrelated to the vaccine.

Another complication that may affect the trial: the Reuters report said the FDA is requesting data from the British pharmaceutical firm that is in a different format than the one used by the FDA.

People familiar with the developments told Reuters the FDA’s actions aren't an indicator there are safety issues related to any of the vaccines under review.

Benzinga is covering every angle of how the coronavirus affects the financial world.

For daily updates,

sign up for our coronavirus newsletter

.

Why It Matters:

Last month, AstraZeneca’s coronavirus vaccine trials were halted after a volunteer developed symptoms of a serious

neurological disorder

known as transverse myelitis.

The Cambridge, United Kingdom-based company has resumed trials in India, South Africa, Brazil and the U.K.

Some scientists have questioned why the drugmaker’s COVID-19 vaccine trials remain suspended in the U.S.

While AstraZeneca experiences delays,

Pfizer Inc

(NYSE:

PFE

) is seeking FDA clearance to expand its late-stage trials by adding more participants.

AZN Price Action:

AstraZeneca shares ended Wednesday's session down 0.54% at $54.81 and fell slightly further after-hours.

See more from Benzinga

Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas

Regeneron Says COVID-19 Antibody Cocktail Helped Non-Hospitalized Patients Heal Faster In Early Trials

Sanofi CEO Says COVID-19 Vaccine Development Process Accelerated, Not Side-Stepped

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

View comments

• ·CME Group (CME) Reports Soft May Volumes, Shares Decline
• ·3 things small business owners should know for 2019
• ·Morning News Call - India, January 3
• ·A robust US job market likely defied shutdown during January
• ·Suzan Craig and Tahi Restore Nature and Make 100 Percent Natural, Genuine Honey
• ·BRIEF-Shenzhen Exchange Filing Shows Block Trade Of Yuto Packaging Technology's Shares
• ·BRIEF-Eurocrane China's Shareholder To Unload Up To 5 Pct Stake Between March 4 And Aug 1
• ·What Kind Of Share Price Volatility Should You Expect For Geospace Technologies Corporation (NASDAQ:GEOS)?
• ·What Does Success Look Like for a Climate Czar?
• ·What To Know Before Buying Premier Financial Bancorp, Inc. (NASDAQ:PFBI) For Its Dividend
• ·Asia Gold: Chinese demand jumps; Indian buyers hold off with eye on budget
• ·Do You Know What Trio Industrial Electronics Group Limited’s (HKG:1710) P/E Ratio Means?
• ·NextEra Energy (NEE) Stock Moves -1.57%: What You Should Know
• ·The Week Ahead – Private Sector PMI, U.S Nonfarm Payrolls, and Central Banks in Focus
• ·Is Best Buy Co., Inc.’s (NYSE:BBY) ROE Of 36% Impressive?
• ·Johnson Controls: Fiscal 1Q Earnings Snapshot